AIMS: To test the feasibility and effectiveness of brief counseling intervention (BCI) and naltrexone integrated into tuberculosis (TB) care in Tomsk, Russia. DESIGN: Using a factorial randomized controlled trial design, patients were randomized into: naltrexone (NTX), brief behavioral compliance enhancement therapy (BBCET), treatment as usual (TAU) and BCI. SETTING AND PARTICIPANTS: In the Tomsk Oblast, hospitalized TB patients diagnosed with alcohol use disorders (AUDs) by the DSM-IV were referred at the start of TB treatment. Of the 196 participants, the mean age was 41 years and 82% were male. Severe TB (84.7% had cavitary disease) and smoking (92.9%) were common. The majority had a diagnosis of an AUD (63.0%); 27.6% reported nearly daily drinking and consumed a median of 16 standard drinks per day. MEASUREMENTS: Primary outcomes were 'favorable' TB outcome (cured, completed treatment) and change in mean number of abstinent days in the last month of study compared with baseline. Change in mean number of heavy drinking days, defined as four drinks per day and five drinks per day for women and men, respectively, and TB adherence, measured as percentage of doses taken as prescribed under direct observation, were secondary outcomes. Analysis based on 'intention-to-treat' was performed for multivariable analysis. FINDINGS: Primary TB and alcohol end-points between naltrexone and no-naltrexone or BCI and no-BCI groups did not differ significantly. TB treatment adherence and change in number of heavy drinking days also did not differ significantly among treatment arms. Among individuals with a prior quitting attempt (n = 111), naltrexone use was associated with an increased likelihood of favorable TB outcomes (92.3% versus 75.9%, P = 0.02). CONCLUSIONS: In Tomsk Oblast, Russia, tuberculosis patients with severe alcohol use disorders who were not seeking alcohol treatment did not respond tonaltrexone or behavioral counselling integrated into tuberculosis care; however, those patients with past attempts to quit drinking had improved tuberculosis outcomes.
RCT Entities:
AIMS: To test the feasibility and effectiveness of brief counseling intervention (BCI) and naltrexone integrated into tuberculosis (TB) care in Tomsk, Russia. DESIGN: Using a factorial randomized controlled trial design, patients were randomized into: naltrexone (NTX), brief behavioral compliance enhancement therapy (BBCET), treatment as usual (TAU) and BCI. SETTING AND PARTICIPANTS: In the Tomsk Oblast, hospitalized TB patients diagnosed with alcohol use disorders (AUDs) by the DSM-IV were referred at the start of TB treatment. Of the 196 participants, the mean age was 41 years and 82% were male. Severe TB (84.7% had cavitary disease) and smoking (92.9%) were common. The majority had a diagnosis of an AUD (63.0%); 27.6% reported nearly daily drinking and consumed a median of 16 standard drinks per day. MEASUREMENTS: Primary outcomes were 'favorable' TB outcome (cured, completed treatment) and change in mean number of abstinent days in the last month of study compared with baseline. Change in mean number of heavy drinking days, defined as four drinks per day and five drinks per day for women and men, respectively, and TB adherence, measured as percentage of doses taken as prescribed under direct observation, were secondary outcomes. Analysis based on 'intention-to-treat' was performed for multivariable analysis. FINDINGS: Primary TB and alcohol end-points between naltrexone and no-naltrexone or BCI and no-BCI groups did not differ significantly. TB treatment adherence and change in number of heavy drinking days also did not differ significantly among treatment arms. Among individuals with a prior quitting attempt (n = 111), naltrexone use was associated with an increased likelihood of favorable TB outcomes (92.3% versus 75.9%, P = 0.02). CONCLUSIONS: In Tomsk Oblast, Russia, tuberculosispatients with severe alcohol use disorders who were not seeking alcohol treatment did not respond to naltrexone or behavioral counselling integrated into tuberculosis care; however, those patients with past attempts to quit drinking had improved tuberculosis outcomes.
Authors: James C Garbutt; Henry R Kranzler; Stephanie S O'Malley; David R Gastfriend; Helen M Pettinati; Bernard L Silverman; John W Loewy; Elliot W Ehrich Journal: JAMA Date: 2005-04-06 Impact factor: 56.272
Authors: Charles S Lieber; David G Weiss; Roberto Groszmann; Fiorenzo Paronetto; Steven Schenker Journal: Alcohol Clin Exp Res Date: 2003-11 Impact factor: 3.455
Authors: Evelyn P Whitlock; Michael R Polen; Carla A Green; Tracy Orleans; Jonathan Klein Journal: Ann Intern Med Date: 2004-04-06 Impact factor: 25.391
Authors: Ann C Miller; A Katrina Nelson; Viktoria Livchits; Shelly F Greenfield; Galina Yanova; Sergei Yanov; Hilary S Connery; Sidney Atwood; Charmaine S Lastimoso; Sonya S Shin Journal: PLoS One Date: 2016-02-12 Impact factor: 3.240
Authors: Rajesh D Deshmukh; D J Dhande; Kuldeep Singh Sachdeva; Achuthan Sreenivas; A M V Kumar; Srinath Satyanarayana; Malik Parmar; Patrick K Moonan; Terrence Q Lo Journal: PLoS One Date: 2015-08-24 Impact factor: 3.240
Authors: Emily A Kendall; Danie Theron; Molly F Franke; Paul van Helden; Thomas C Victor; Megan B Murray; Robin M Warren; Karen R Jacobson Journal: PLoS One Date: 2013-12-13 Impact factor: 3.240
Authors: Thelma E Tupasi; Anna Marie Celina G Garfin; Ekaterina V Kurbatova; Joan M Mangan; Ruth Orillaza-Chi; Leilani C Naval; Glenn I Balane; Ramon Basilio; Alexander Golubkov; Evelyn S Joson; Woo-Jin Lew; Vivian Lofranco; Mariquita Mantala; Stuart Pancho; Jesus N Sarol Journal: Emerg Infect Dis Date: 2016-03 Impact factor: 6.883
Authors: Karthickeyan Duraisamy; Sunilkumar Mrithyunjayan; Smita Ghosh; Sreenivas Achuthan Nair; Shibu Balakrishnan; Jayasankar Subramoniapillai; John E Oeltmann; Patrick K Moonan; Ajay M V Kumar Journal: Ann Am Thorac Soc Date: 2014-06